Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Status and phase: Completed; Phase 2

Conditions: Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma

Treatments: Drug: Vorinostat; Other: Laboratory Biomarker Analysis; Drug: Bortezomib

Study type: Interventional

Funder types: NIH

Identifiers

NCT00703664

N01CM62208 (U.S. NIH Grant/Contract)

N01CM00071 (U.S. NIH Grant/Contract)

MCC-15428 (Other Identifier)

P30CA076292 (U.S. NIH Grant/Contract)

N01CM62201 (U.S. NIH Grant/Contract)

NCI-2009-00275 (Registry Identifier)

8064 (Other Identifier)

N01CM62204 (U.S. NIH Grant/Contract)

N01CM00100 (U.S. NIH Grant/Contract)

CDR0000598308

Details and patient eligibility

About

This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Full description

This was a multicenter, non-randomized phase 2 trial using a Simon two-stage design with 3 cohorts.

PRIMARY OBJECTIVES:

I. Estimate the response rates of mantle cell and diffuse large B-cell lymphomas to bortezomib and vorinostat combination therapy.

SECONDARY OBJECTIVES:

I. Assess the safety and tolerability of the study regimen. II. Observe progression-free survival and response durations. III. Observe the relationship between pretreatment lymphoma cell nuclear v-rel reticuloendotheliosis viral oncogene homolog A (relA) and response.

OUTLINE:

Patients receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Patients also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Enrollment: 65 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed mantle cell or diffuse large B-cell lymphoma; histological material must be available for central pathological review; unstained histological material -- slides or blocks -- must be available for correlative studies; archived material from previous biopsies is acceptable, unless a patient's lymphoma has been known to undergo histological transformation in the past, in which case a repeat biopsy to confirm histology prior to enrollment is required; availability of material must be confirmed at the time of registration, but material may be submitted subsequent to registration and initiation of study treatment

• Measurable disease according to the Revised Response Criteria for Malignant Lymphoma; this requires at least one lesion greater than 1.0 cm in diameter in both the long and short axis as measured by spiral computed tomography (CT) scan or physical exam

• Prior allogeneic stem cell transplant is allowed provided that all of the following conditions are met:

  • >= 6 months have elapsed since allogeneic transplant
  • No graft vs. host disease (GVHD) is present
  • Not currently on immunosuppressive therapy

• Prior therapy:

  • Mantle cell lymphoma:

    • Previously treated or untreated
    • No prior bortezomib

  • Diffuse large B-cell lymphoma:

    • At least one prior systemic therapy

    • No prior bortezomib

      • Note: Not intended for patients in first relapse who are candidates for high dose therapy with stem cell support

• Life expectancy of greater than 3 months

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

• Able to tolerate loperamide or other anti-diarrheal medications

• Absolute neutrophil count >= 1.5 x 10^9/L

• Platelets >= 75 x 10^9/L

• Total bilirubin =< 1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transferase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal

• Creatinine within normal institutional limits or calculated creatinine clearance >= 60 mL/min according to the Cockcroft-Gault formula

• For patients with known human immunodeficiency virus (HIV) infection, a cluster of differentiation (CD)4 count >= 0.5 x 10^9/L

• For patients whose last treatment included bendamustine or fludarabine, a CD4 count >= 0.4 x 10^9/L

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and to report pregnancy or suspected pregnancy while participating in the study

• Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

• Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study
• Prior histone deacetylase inhibitor as cancer treatment
• Concurrent treatment with other investigational agents
• Plans for other concurrent cancer treatment; if steroids for cancer control have been used, patients must be off these agents for >= 1 week before starting treatment; exception: maintenance therapy for non-malignant disease with prednisone or steroid equivalent dose < 10 mg/day is permitted
• History of brain metastasis including leptomeningeal metastasis
• Grade >= 2 neuropathy, regardless of cause
• Unable to take oral medications
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib or vorinostat
• Not sufficiently recovered from previous treatment
• Medical or other condition (for example: uncontrolled infection; potentially life threatening changes on electrocardiogram [EKG]) or concurrent treatment (for example, marrow suppressive agents such as zidovudine) that represents an inappropriate risk to the patient or likely would compromise achievement of the primary study objective; patients should be closely monitored when given bortezomib in combination with the cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors and inducers
• Pregnant women are excluded from this study; breastfeeding should be discontinued
• Active concurrent malignancy, except adequately treated non-melanoma skin cancer

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

65 participants in 1 patient group

Treatment (vorinostat, bortezomib)

Experimental group

Description:

Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically. Treatment arm consists of 3 cohorts, all receiving the same treatment: A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib. B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib. C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib.

Treatment:

Other: Laboratory Biomarker Analysis

Drug: Bortezomib

Drug: Vorinostat